Priscilla Wander

Ms. Priscilla Wander

Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2020 in Haematologica
Verified
Journal Article
Open access
PDF file
SNSanne Noort
Sanne Noort
PWPriscilla Wander
Priscilla Wander
TATodd A. Alonzo
Todd A. Alonzo
JSJenny Smith
Jenny Smith
RRRhonda E. Ries
Rhonda E. Ries
SMSoheil Meshinchi
Soheil Meshinchi

1 February 2018 in Haematologica
Verified
Journal Article
Closed access
PDF file
MKMark Kerstjens
Mark Kerstjens
SPSandra S. Pinhancos
Sandra S. Pinhancos
PCPatricia Garrido Castro
Patricia Garrido Castro
PSPauline Schneider
Pauline Schneider
PWPriscilla Wander
Priscilla Wander
RSRonald W. Stam
Ronald W. Stam

1 May 2021 in Translational Oncology
Verified
Journal Article
Open access
PWPriscilla Wander
Priscilla Wander
SASusan T.C.J.M. Arentsen-Peters
Susan T.C.J.M. Arentsen-Peters
SPSandra S. Pinhanҫos
Sandra S. Pinhanҫos
BKBianca Koopmans
Bianca Koopmans
MDM.EMmy M. Dolman
M.EMmy M. Dolman
RSRonald W. Stam
Ronald W. Stam
Pediatric MLL-rearranged acute myeloid leukemia (AML) has a generally unfavorable outcome, primarily due to relapse and drug resistance. To overcome these difficulties, new therapeutic agents are urgently needed. Yet, implementing novel drugs for clinical use is a time-consuming, laborious, costly and high-risk process. Therefore, we applied a drug-repositioning strategy by screening drug libraries, comprised of >4000 compounds that are mostly FDA-approved, in a high-throughput format on primary MLL-rearranged AML cells. Here we identified pyrvinium pamoate (pyrvinium) as a novel candidate drug effective against MLL-rearranged AML, eliminating all cell viability at <1000 nM. Additional screening of identified drug hits on non-leukemic bone marrow samples, resulted in a decrease in cell viability of ∼50% at 1000 nM pyrvinium, suggesting a therapeutic window for targeting leukemic cells specifically. Validation of pyrvinium on an extensive panel of AML cell lines and primary AML samples showed comparable viabilities as the drug screen data, with pyrvinium achieving IC50 values of <80 nM in these samples. Remarkably, pyrvinium also induced cell toxicity in primary MLL-AF10+ AML cells, an MLL-rearrangement associated with a poor outcome. While pyrvinium is able to inhibit the Wnt pathway in other diseases, this unlikely explains the efficacy we observed as β-catenin was not expressed in the AML cells tested. Rather, we show that pyrvinium co-localized with the mitochondrial stain in cells, and hence may act by inhibiting mitochondrial respiration. Overall, this study shows that pyrvinium is highly effective against MLL-rearranged AML in vitro, and therefore represents a novel potential candidate for further studies in MLL-rearranged AML.

2 June 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
PWPriscilla Wander
Priscilla Wander
LCLaurence C Cheung
Laurence C Cheung
SPSandra S. Pinhanҫos
Sandra S. Pinhanҫos
LJLuke Jones
Luke Jones
MKMark Kerstjens
Mark Kerstjens
RSRonald W. Stam
Ronald W. Stam

23 June 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
MKMark Kerstjens
Mark Kerstjens
PCPatricia Garrido Castro
Patricia Garrido Castro
SPSandra S. Pinhanços
Sandra S. Pinhanços
PSPauline Schneider
Pauline Schneider
PWPriscilla Wander
Priscilla Wander
RSRonald W. Stam
Ronald W. Stam
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) remains one of the most aggressive types of childhood hematologic malignancy. The majority (~80%) of infant ALL cases are characterized by chromosomal translocations involving the MLL (or KMT2A) gene, which confer highly dismal prognoses on current combination chemotherapeutic regimens. Hence, more adequate therapeutic strategies are urgently needed. To expedite clinical transition of potentially effective therapeutics, we here applied a drug repurposing approach by performing in vitro drug screens of (mostly) clinically approved drugs on a variety of human ALL cell line models. Out of 3685 compounds tested, the alkaloid drug Camptothecin (CPT) and its derivatives 10-Hydroxycamtothecin (10-HCPT) and 7-Ethyl-10-hydroxycamtothecin (SN-38: the active metabolite of the drug Irinotecan) appeared most effective at very low nanomolar concentrations in all ALL cell lines, including models of MLL-rearranged ALL (n = 3). Although the observed in vitro anti-leukemic effects of Camptothecin and its derivatives certainly were not specific to MLL-rearranged ALL, we decided to further focus on this highly aggressive type of leukemia. Given that Irinotecan (the pro-drug of SN-38) has been increasingly used for the treatment of various pediatric solid tumors, we specifically chose this agent for further pre-clinical evaluation in pediatric MLL-rearranged ALL. Interestingly, shortly after engraftment, Irinotecan completely blocked leukemia expansion in mouse xenografts of a pediatric MLL-rearranged ALL cell line, as well as in two patient-derived xenograft (PDX) models of MLL-rearranged infant ALL. Also, from a more clinically relevant perspective, Irinotecan monotherapy was able to induce sustainable disease remissions in MLL-rearranged ALL xenotransplanted mice burdened with advanced leukemia. Taken together, our data demonstrate that Irinotecan exerts highly potent anti-leukemia effects against pediatric MLL-rearranged ALL, and likely against other, more favorable subtypes of childhood ALL as well.

10 March 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
PWPriscilla Wander
Priscilla Wander
SASusan T. C. J. M. Arentsen-Peters
Susan T. C. J. M. Arentsen-Peters
KVKirsten S. Vrenken
Kirsten S. Vrenken
SPSandra Mimoso Pinhanҫos
Sandra Mimoso Pinhanҫos
BKBianca Koopmans
Bianca Koopmans
RSRonald W. Stam
Ronald W. Stam
KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants (<1 year of age) represents an aggressive type of childhood leukemia characterized by a poor clinical outcome with a survival chance of <50%. Implementing novel therapeutic approaches for these patients is a slow-paced and costly process. Here, we utilized a drug-repurposing strategy to identify potent drugs that could expeditiously be translated into clinical applications. We performed high-throughput screens of various drug libraries, comprising 4191 different (mostly FDA-approved) compounds in primary KMT2A-rearranged infant ALL patient samples (n = 2). The most effective drugs were then tested on non-leukemic whole bone marrow samples (n = 2) to select drugs with a favorable therapeutic index for bone marrow toxicity. The identified agents frequently belonged to several recurrent drug classes, including BCL-2, histone deacetylase, topoisomerase, microtubule, and MDM2/p53 inhibitors, as well as cardiac glycosides and corticosteroids. The in vitro efficacy of these drug classes was successfully validated in additional primary KMT2A-rearranged infant ALL samples (n = 7) and KMT2A-rearranged ALL cell line models (n = 5). Based on literature studies, most of the identified drugs remarkably appeared to lead to activation of p53 signaling. In line with this notion, subsequent experiments showed that forced expression of wild-type p53 in KMT2A-rearranged ALL cells rapidly led to apoptosis induction. We conclude that KMT2A-rearranged infant ALL cells are vulnerable to p53 activation, and that drug-induced p53 activation may represent an essential condition for successful treatment results. Moreover, the present study provides an attractive collection of approved drugs that are highly effective against KMT2A-rearranged infant ALL cells while showing far less toxicity towards non-leukemic bone marrow, urging further (pre)clinical testing.